A detailed history of Affinity Asset Advisors, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 50,000 shares of PCVX stock, worth $4.35 Million. This represents 0.99% of its overall portfolio holdings.

Number of Shares
50,000
Previous 60,000 16.67%
Holding current value
$4.35 Million
Previous $4.53 Million 26.0%
% of portfolio
0.99%
Previous 0.62%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$70.52 - $117.12 $705,200 - $1.17 Million
-10,000 Reduced 16.67%
50,000 $5.71 Million
Q2 2024

Aug 14, 2024

SELL
$60.06 - $78.77 $1.2 Million - $1.58 Million
-20,000 Reduced 25.0%
60,000 $4.53 Million
Q1 2024

May 14, 2024

BUY
$59.79 - $81.05 $3.29 Million - $4.46 Million
55,000 Added 220.0%
80,000 $5.46 Million
Q3 2023

Nov 14, 2023

BUY
$46.0 - $53.1 $509,542 - $588,188
11,077 Added 79.56%
25,000 $1.27 Million
Q2 2023

Aug 14, 2023

SELL
$34.66 - $54.07 $1.67 Million - $2.61 Million
-48,300 Reduced 77.62%
13,923 $695,000
Q1 2023

May 15, 2023

BUY
$36.27 - $47.2 $80,628 - $104,925
2,223 Added 3.71%
62,223 $2.33 Million
Q4 2022

Feb 13, 2023

BUY
$20.58 - $47.95 $1.23 Million - $2.88 Million
60,000 New
60,000 $2.88 Million
Q4 2021

Feb 11, 2022

SELL
$19.32 - $26.45 $966,000 - $1.32 Million
-50,000 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$16.45 - $24.06 $329,000 - $481,200
20,000 Added 66.67%
50,000 $1.13 Million
Q4 2020

Feb 12, 2021

BUY
$26.57 - $51.74 $797,100 - $1.55 Million
30,000 New
30,000 $797,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.17B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.